<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03750643</url>
  </required_header>
  <id_info>
    <org_study_id>17090</org_study_id>
    <secondary_id>J1B-MC-FRCC</secondary_id>
    <nct_id>NCT03750643</nct_id>
  </id_info>
  <brief_title>A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis</brief_title>
  <official_title>Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the safety, tolerability, and efficacy of
      the study drug known as LY3454738 in healthy participants and participants with atopic
      dermatitis. The study has three parts. Each participant will enroll in one part. The study
      will last 12 to 24 weeks, depending on part.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Anticipated">January 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving a Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 or 1 with a ≥ 2-point Improvement from Baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>The vIGA-AD measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) of LY3454738</measure>
    <time_frame>Day 1 through Day 85 (Day 99 for Part C)</time_frame>
    <description>Cmax of LY3454738</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Versus-Time Curve (AUC) of LY3454738</measure>
    <time_frame>Day 1 through Day 85 (Day 99 for Part C)</time_frame>
    <description>AUC of LY3454738</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>LY3454738 - Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of LY3454738 administered intravenously (IV) or subcutaneously (SC) to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3454738 - Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3454738 administered IV to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3454738 - Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3454738 administered IV to participants with atopic dermatitis (AD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Part C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV to participants with AD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3454738</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3454738 - Part A</arm_group_label>
    <arm_group_label>LY3454738 - Part B</arm_group_label>
    <arm_group_label>LY3454738 - Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3454738</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3454738 - Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo - Part A</arm_group_label>
    <arm_group_label>Placebo - Part B</arm_group_label>
    <arm_group_label>Placebo - Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All: Must have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m²),
             inclusive, for Parts A and B, and 18.0 to 45.0 kg/m², inclusive, for Part C and a
             minimum body weight of 50 kilograms

          -  For PART A and B only, regarding the inclusion of healthy Japanese participants:
             Minimum age is 20 years and the participant's biological parents and all of the
             participant's biological grandparents must be of exclusive Japanese descent and must
             have been born in Japan

          -  AD:

               -  Must have a diagnosis of AD for at least 12 months with either poor response to
                  topical treatments or inability to use topical treatments

               -  Must agree to use moisturizer daily throughout the treatment period

        Exclusion Criteria:

          -  All: must not have previously completed a clinical trial with a molecule targeting
             interleukin-33 (IL-33) or its receptor

          -  AD:

               -  Must not have received certain topical medications for AD within 2 weeks prior to
                  randomization

               -  Must not have received certain oral medications for AD or received phototherapy
                  within 4 weeks prior to randomization

               -  Must not have received any antibody-based biologic agents (marketed or
                  investigational) within 5 half lives (t1/2) of the drug prior to randomization

               -  Must not have received intravenous, intramuscular, or intra-articular steroids in
                  the past 6 weeks prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>256-236-0055</phone>
    </contact>
    <investigator>
      <last_name>Stacy J Haynes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Revival Research Corporation</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-982-8892</phone>
    </contact>
    <investigator>
      <last_name>Delilah A Alonso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Global Health Research Center</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-824-0026</phone>
    </contact>
    <investigator>
      <last_name>Blanca N Gonzales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8132642155</phone>
    </contact>
    <investigator>
      <last_name>Seth Benjamin Forman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mira Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Sciences, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>502-451-9000</phone>
    </contact>
    <investigator>
      <last_name>Leon H Kircik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PAREXEL-Phase 1 Baltimore Harbor Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>248-716-7009</phone>
    </contact>
    <investigator>
      <last_name>Tina GL Pickett-Baisden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>702-597-9825</phone>
    </contact>
    <investigator>
      <last_name>Michael B. Jacobs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wright State Physicians Dermatology</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>46435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Bryant Travers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4053290474</phone>
    </contact>
    <investigator>
      <last_name>Paul Stevens Gillum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>210-614-5557</phone>
    </contact>
    <investigator>
      <last_name>Mark S Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>509-343-3710</phone>
    </contact>
    <investigator>
      <last_name>William P. Werschler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/atopic-dermatitis/FRCC#?postal=</url>
    <description>Click here for more information about this study: A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis (Eczema)</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

